Hydroxychloroquine and Unexplained Recurrent Miscarriage

• Status: Active, not recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

Recurrent miscarriage affects women of childbearing age worldwide. Vascular endothelial dysfunction and immunological impairment are associated with both recurrent miscarriage and preeclampsia. To date, there is no effective or optimal therapeutic approach for these conditions. Hydroxychloroquine has endothelial protective action via ant diabetic, lipid lowering, antioxidant effects or direct endothelial protection. Hydroxychloroquine is an antimalarial and immunomodulatory agent. In pregnancy, hydroxychloroquine is prescribed for inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve placental function in pregnancies associated with heightened inflammation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Aspirin; Folic Acid; Hydroxychloroquine

Criteria

Inclusion Criteria:

• Women had at least 2 previous miscarriage before 20 weeks.

• Women trying to conceive.

• No anatomical or endocrine cause of recurrent pregnancy loss.

• Women who have given their informed consent.

• The negative antibody test for antiphospholipid syndrome

Exclusion Criteria:

• Women who are already pregnant.

• Known contraindication to treatment by Hydroxychloroquine (

• Patients already using Hydroxychloroquine

• Impossible to follow-up.